Omega Systems Acquires PEAKE Technology Partners | Optain Health Acquires EyePACS | BioIVT Acquires BeCytes

Take a look at today’s highlighted firms that have actually lately finished an M&An offer, and make certain to have a look at the complete checklist of past healthcare IT M&A.

Omega Equipments Increases Medical Care MSP Management with Purchase of PEAKE Innovation Allies

Omega Systems, a leading service provider of handled IT, cybersecurity, and conformity solutions to controlled sectors, today revealed the purchase of PEAKE Technology Partners, a medical care took care of companies focusing on certified innovation services for doctor and experts throughout the Mid-Atlantic.

The purchase reinforces Omega’s placement as a leading MSP and MSSP for the health care sector, increasing its technological abilities, local impact, and understanding of the IT, expert system, and governing conformity difficulties encountering clinical methods, doctor teams, and various other health care companies across the country.

” PEAKE brings deep health care competence, consumer emphasis, and they share our core worths and people-first society,” stated Omega Solution chief executive officer Mike Fuhrman. “With each other, we’re much better located than ever before to assist doctor and experts improve treatment shipment with self-confidence– providing services that secure information, boost procedures, and eventually sustain much better client end results.”

Established In 2014 and based in Bowie, Maryland, PEAKE offers thorough handled IT solutions, information safety and security, conformity, and cloud services made specifically for health care companies …

Full release here, initially revealed November 5th, 2025.

Optain Health And Wellness Gets EyePACS to Broaden Accessibility to Next-Generation Retinal Imaging for Medical Care and Advancement Oculomics

Optain Health, a medical care innovation firm using expert system (AI), robot retinal imaging, and teleophthalmology to find eye and systemic condition previously, today revealed the purchase of EyePACS, the united state’s biggest and most well-known teleophthalmology network. The collaboration unifies 2 mission-aligned leaders to broaden accessibility to retinal testing in medical care.

For greater than 20 years, EyePACS has actually powered community-based eye-disease testing throughout greater than 740 scientific websites, consisting of FQHCs, region wellness systems, and home-health programs. The network has actually determined greater than 140,000 people with serious sight-threatening condition amongst 1.5 million individuals evaluated.

Optain’s innovation improves and reinforces the EyePACS community-based testing network. It brings sophisticated AI ability and next-generation robot retinal imaging that make it possible for quick, top quality photo capture without expansion or driver competence, making retinal imaging feasible any place individuals get treatment.

A common objective to stop loss of sight and boost wellness: After 2 years of close partnership, Optain and EyePACS are signing up with pressures around a common objective: to stop preventable loss of sight and boost systemic wellness via quickly, obtainable, and top quality retinal imaging …

Full release here, initially revealed November sixth, 2025.

BioIVT Invites BeCytes: Increasing International Accessibility to Fairly Sourced Human Biospecimens for Study

BioIVT, a worldwide research study companion and biospecimen services service provider for medicine and analysis advancement, today revealed the purchase of BeCytes Biotechnologies, a Barcelona, Spain-based firm focusing on the control of the collection, handling, and circulation of top quality human cells and cells for biomedical research study. This notes BioIVT’s ongoing technique to broaden in crucial company systems sustaining NAMs and absorption, circulation, metabolic process, and discharging (ADME) locations.

The enhancement of BeCytes reinforces BioIVT’s European impact and broadens accessibility to fairly sourced, top quality biospecimens– specifically main hepatocytes– for scientists worldwide. BeCytes’ deep competence in cells sourcing and main cell seclusion matches BioIVT’s existing biospecimen services and research study solutions, consisting of those in New Method Methodologies (NAMs).

” As international need boosts for NAMs and even more anticipating research study versions, accessibility to fairly sourced cells and cells has actually never ever been much more essential,” stated Richard Haigh, Chief Executive Officer at BioIVT. “With this purchase, we’re increasing our reach, improving our profile, and offering researchers the top quality samplings they require to drive advancement and increase clinical advancements.”

Established In 2015, BeCytes has actually sealed itself as a relied on companion to pharmaceutical, biotech, and scholastic scientists looking for the control of human cells purchase and cell items generation …

Full release here, initially revealed November fourth, 2025.